NEW YORK (GenomeWeb News) – Cell Signaling Technology today announced it has licensed its patent rights and proprietary antibody reagents related to the detection of epidermal growth factor receptor mutations to Ventana Medical Systems.
The non-exclusive licensing agreement is for the field of tissue-based in vitro diagnostics testing, the Danvers, Mass.-based antibody firm said. Financial and other terms of the deal were not disclosed.
CST developed and clinically validated mutation-specific EGFR antibodies through its internal Cancer Biomarker Program.
Ventana, headquartered in Tucson, Ariz., is owned by Roche and develops and manufactures instruments and reagents for tissue-based cancer diagnostics.